Randal S. Shelton

Role not yet determined Is this you? Add your title

UAMS

Also affiliated: University of Arkansas Medical Center (2024)

5 h-index 20 pubs 72 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Randal S. Shelton's research focuses on cancer treatment and pharmacology, with recent work investigating novel therapeutic strategies for hepatocellular carcinoma and multiple myeloma. His publications include studies on enhancing immune responses and survival in hepatocellular carcinoma models through oncolytic virus therapy and immune checkpoint blockade. He has also explored PHF19 inhibition as a therapeutic target in multiple myeloma. Additionally, Shelton's research extends to the impact of materials science on health, with a publication addressing the risk assessment of carbon nanotubes for agricultural applications. His work on pancreatic cancer involves targeting the tumor microenvironment to improve resectability. Collaborations include extensive work with Alexei G. Basnakian, Steven R. Post, Martin J. Cannon, and Mulu Z. Tesfay at the University of Arkansas for Medical Sciences.

Metrics

h-index: 5
Publications: 20
Citations: 72

Selected Publications

Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)

Cancer Research DOI OpenAlex
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)

Journal for ImmunoTherapy of Cancer DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

Cancer Research DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

Biomedicines 6 citations DOI OpenAlex
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)

Cancer Research DOI OpenAlex
Endonuclease G (EndoG) Inhibits DNase I-Mediated Apoptosis and DNA Repair in Kidney Tubular Epithelial Cells During Cisplatin Injury (2023)

Journal of the American Society of Nephrology DOI OpenAlex
Comprehensive Risk Assessment of Carbon Nanotubes Used for Agricultural Applications (2022)

ACS Nano 24 citations DOI OpenAlex
PHF19 inhibition as a therapeutic target in multiple myeloma (2021)

Current Research in Translational Medicine 9 citations DOI OpenAlex
The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma (2019)

Blood DOI OpenAlex
Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors (2018)

Blood DOI OpenAlex
Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice (2017)

JBMR Plus 19 citations DOI OpenAlex
Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients (2016)

Blood 3 citations DOI OpenAlex
Utility of an allograft tendon for scoliosis correction via the costo‐transverse foreman (2016)

Journal of Orthopaedic Research® 2 citations DOI OpenAlex
Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1 (2014)

Blood 1 citation DOI OpenAlex